Behcet disease drug Market
Global Behcet disease drug Market Size, Share & Trends Analysis Report by drug (Corticosteroid, Adalimumab Biosimilar, Infliximab Biosimilar, Apremilast, And Canakinumab) And By Route Of Administration (Oral, Intravenous, Intramuscular and Topical), Forecast 2022-2028
The global Behcet disease drug market is anticipated to grow at a considerable CAGR during the forecast period. Behcet disease is known as behcet syndrome. It is a disorder that occurs in different parts of the body. Inflammation of blood vessels occurs in parts of the body like the mouth, genitals, skin, and eyes. The first sign which is seen in Behcet disease is painful mouth ulcers. These ulcers are known as aphthous which occur on lips, tongue, inside cheeks, upper mouth layer, and tonsils. These ulcers are also seen on the scrotum in men and on labia in women. Some people experience painful acne filled with puss on the skin. Erythema nodosum is red nodules that develop in some people. These nodules develop in the arms, legs, and neck. For instance, in Dec 2021, in a study published in the journal of the American Academy of dermatology, it has been found that ustekinumab has been found safe for the treatment of Behcet disease. Successful results were found in the phase 2 study.
Impact of COVID-19 Pandemic on Global Behcet disease drug Market
Covid-19 pandemic has affected every sector of the world in some way. Behcet disease drug market suffered a short dip during the pandemic as there were restrictions in hospital facilities and only a few emergency services were open. Treatment for the long-term disease was not possible during this time as it required regular follow-up checkups which were not possible during covid-19, all these lead to the decrease in market growth.
Segmental Outlook
The global behcet disease drug market is segmented based on drug, and route of administration. Based on drug, the market is segmented into corticosteroid, adalimumab biosimilar, infliximab biosimilar, apremilast and canakinumab . Based on the route of administration, the market is sub-segmented into oral, intravenous, intramuscular, and topical.
Global Behcet disease drug Market Share by Drug, 2021 (%)
Apremilast is Anticipated to Hold a Prominent Share in the Global Behcet disease drug Market
Apremilast is anticipated to hold a prominent market share in the global Behcet disease drug market during the forecast period. It is an oral phosphodiesterase 4 inhibitors. Apremilast is approved by the Food and Drug Administration of the US. It is mainly used for the treatment of oral ulcers which are caused by Behcet disease. According to the American Behcet disease association, in around 100,000 people in the US, around 5 people are affected by Behcet disease. As per the same association, Apremilast was found safe in a placebo-controlled phase 3 relief study, in which around 207 members were taken for study. For instance, in Dec 2021, Amgen announced that FDA in the US has approved Otezla (Apremilast) for the treatment of plaque psoriasis in adults.
Regional Outlooks
The global Behcet disease drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America is anticipated to lead the Behcet disease drug market during the forecast period. Europe is accounted for the second-most lucrative region due to improved healthcare facilities and increasing awareness of people for early treatment of behcet’s disease in the region. The Asia Pacific is expected to register prominent growth over the forecast period, owing to the increasing patients suffering from behcet’s disease.
Global Behcet disease drug Market Growth, by region 2022-2028
North America is Estimated to Hold the Major Share in the Global Behcet disease drug Market
Geographically, it is anticipated that the major share of the market will be taken by North America and this region will lead during the forecast period. A major factor for the regional growth is attributed to the increasing launches made by market players in the field of dermatology. They are increasing their portfolio size which in turn is making available options for the treatment of diseases related to dermatology. An increase in therapy related to Behcet disease is opening doors for the successful treatment of this disease. For instance, in Sept 2021, Amgen announced that it will present data from its portfolio of inflammable disease drugs at the European Academy of Dermatology and venereology 30th congress. It will present data relating to future drug launches.
Market Players Outlook
The major companies serving the global Behcet disease drug market include Abbvie Inc., Celgene Corp., Cell Medica Ltd., Cohersu biosciences Inc., Genor biopharma Corp.Ltd. and others. The market players are working in a consistent way to provide their consumers with reliable options in this field. And for this, they are adopting different market strategies such as mergers and acquisitions, new product launches, business expansion, partnership collaboration, and others. For instance, in July 2021, Aristea Therapeutics completed a $63 million financing to move further growth in the treatment of inflammatory disease.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Behcet disease drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Behcet disease drug Market
• Recovery Scenario of Global Behcet disease drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Abbvie Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Celgene Corp.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Cell medica Ltd.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Coherus biosciences Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Genor biopharma Co., Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Behcet disease drug Market by Drug TYPE
4.1.1. Corticosteroids
4.1.2. Adalimumab biosimilar
4.1.3. Infliximab biosimilar
4.1.4. Apremilast
4.1.5. Canakinumab
4.2. Global Behcet disease drug Market by Route of Administration
4.2.1. Oral
4.2.2. Intravenous
4.2.3. Intramuscular
4.2.4. Topical
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Biocon Ltd.
6.3. F. Hoffmann-La Roche Ltd.
6.4. Hospira Inc.
6.5. Intas Pharmaceutical
6.6. Novartis AG
6.7. Panacea Biotec Ltd.
6.8. R Pharm
1. GLOBAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CORTICOSTEROIDS BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ADALIMUMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL INFLIXIMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL APREMILAST BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL CANAKINUMAB BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
8. GLOBAL ORAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL INTRAVENOUS BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL INTRAMUSCULAR BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL TOPICAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
15. NORTH AMERICAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
16. EUROPEAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
18. EUROPEAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS DRUG, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
22. REST OF THE WORLD BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. REST OF THE WORLD BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
24. REST OF THE WORLD BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL BEHCET DISEASE DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL BEHCET DISEASE DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL BEHCET DISEASE DRUG MARKET, 2021-2027 (%)
4. GLOBAL BEHCET DISEASE DRUG MARKET SHARE BY DRUG, 2021 VS 2028 (%)
5. GLOBAL CORTICOSTEROID BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL ADALIMUMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL INFLIXIMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL APREMILAST BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL CANAKINUMAB BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL BEHCET DISEASE DRUG MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
11. GLOBAL ORAL BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL INTRAVENOUS BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL INTRAMUSCULAR BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL TOPICAL BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. UK BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
